Conexeu Sciences Inc. (NasdaqCM: CNXU)
Health Care · Biotechnology · US
$3.45
+11.29% today · -76.3% 1Y
Conexeu Sciences Inc. (NasdaqCM: CNXU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $87.44M and employs 4 people.
Over the last twelve months the share price has lost 76.3%, trading between 3.10 and 18.79.
Tweenvest scores Conexeu Sciences Inc. across four factors: quality 44/100, value 70/100. Its strongest factor is value.
CNXU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $87.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.63
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $18.79
- 52-week low
- $3.10
- Avg volume (3M)
- —
- Shares outstanding
- 28.21M
- Employees
- 4
- Next earnings
- —
About Conexeu Sciences Inc.
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
- ISIN
- US20715F1003
- Founded
- 2022
- Listed since
- May 21, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ImmuCell CorporationNasdaqCM: ICCC | $88.55M | $9.75 | 0.00% |
| AnGes, Inc.TSE: 4563 | $88.51M | ¥35.00 | -2.78% |
| ViGenCell Inc.KOSDAQ: A308080 | $88.44M | ₩5,810.00 | +1.57% |
| MediciNova, Inc.NasdaqGM: MNOV | $87.61M | $1.54 | -13.48% |
| 3D Medicines Inc.SEHK: 1244 | $87.44M | HK$2.79 | +4.30% |
| Cardiff Oncology, Inc.NasdaqCM: CRDF | $87.13M | $1.06 | -5.36% |
| ReproCELL IncorporatedTSE: 4978 | $86.89M | ¥132.00 | -6.38% |
| Revium Rx.OTCPK: RVRC | $86.84M | $— | — |
Figures last refreshed Oct 4, 2026.